RESEARCH REPORT Leah Lawrence The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in average-risk men based upon evidence from a systematic literature review. The guideline, which was announced during the 2013 AUA Annual Meeting, recommends that men aged 55 to 69 years who are considering undergoing prostate cancer screening should talk with their physicians about the benefits and risks of screening.
RESEARCH REPORT Leah Lawrence Radium-223 dichloride (Xofigo) received US Food and Drug Administration (FDA) approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has metastasized to the bone but no other organs. The approval came 3 months ahead of schedule under the FDA’s priority review program.
RESEARCH REPORT Anna Azvolinsky A cohort-based study found that men with prostate cancer who took cholesterol-lowering statins had a lower risk of dying from their prostate cancer.
RESEARCH REPORT Anna Azvolinsky A case-control study of almost 500 men suggests that obese men who have had a benign prostate biopsy have a greater risk of prostate cancer in the future.
REVIEW ARTICLE Rajan T. Gupta et al;ONCOLOGY Vol. 27 No. 4 Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences.
REVIEW ARTICLE Matvey Tsivian, et al;ONCOLOGY Vol. 26 No. 12 In this review we focus on the recent evolution of the concept of focal therapy and the potential applications of this management approach within an array of options currently available for patients with localized prostate cancer.
The comparison of brachytherapy and surgery may be done on several levels. This review focuses the comparison on toxicity, the “soft” endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the “hard” endpoint of prostate cancer–specific mortality.
• Further Perspectives on Treating Localized Prostate Cancer
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
This slide show features images of diffuse osteoblastic bone metastases in a 70-year-old advanced prostate cancer patient, bone metastases in the... More »
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction... More »
The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in... More »
Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has... More »
The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate... More »
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
A threshold has clearly been crossed in the management of advanced prostate cancer; however, the impact on survival has been relatively modest, and efforts at personalized therapy have lagged behind those for other solid tumors.
This article presents a review of the literature on screening for prostate cancer with PSA testing; we include a detailed discussion of potential explanations for the contradictory results of the two largest randomized trials as well as reflections on the future of prostate cancer screening.
Although the majority of patients with advanced prostate cancer have an initial response to androgen deprivation, essentially all patients eventually progress to a castration-resistant state, manifested by rising levels of prostate-specific antigen (PSA),
In recent years new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use.
The increase in the prevalence of obesity, diabetes, dyslipidemia, and hypertension has resulted in a marked increase in the prevalence of metabolic syndrome.
The comparison of brachytherapy and surgery may be done on several levels. This review focuses the comparison on toxicity, the “soft” endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the “hard” endpoint of prostate cancer–specific mortality.
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
An asymptomatic, 57-year-old man underwent a prostatic biopsy.
Core biopsy of prostate from an elderly male. Your diagnosis is:
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
